Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-021649
Filing Date
2020-08-12
Accepted
2020-08-12 17:01:09
Documents
53
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0620_relmadatherape.htm 10-Q 398514
2 CERTIFICATION f10q0620ex31-1_relmadathe.htm EX-31.1 9306
3 CERTIFICATION f10q0620ex31-2_relmadathe.htm EX-31.2 9135
4 CERTIFICATION f10q0620ex32-1_relmadathe.htm EX-32.1 3894
5 CERTIFICATION f10q0620ex32-2_relmadathe.htm EX-32.2 3760
  Complete submission text file 0001213900-20-021649.txt   2621151

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE rlmd-20200630.xml EX-101.INS 303038
7 XBRL SCHEMA FILE rlmd-20200630.xsd EX-101.SCH 40930
8 XBRL CALCULATION FILE rlmd-20200630_cal.xml EX-101.CAL 23194
9 XBRL DEFINITION FILE rlmd-20200630_def.xml EX-101.DEF 175599
10 XBRL LABEL FILE rlmd-20200630_lab.xml EX-101.LAB 370373
11 XBRL PRESENTATION FILE rlmd-20200630_pre.xml EX-101.PRE 187560
Mailing Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022
Business Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39082 | Film No.: 201096083
SIC: 2834 Pharmaceutical Preparations